Introduction
Interleukin-6, IL-6, is a major tumor-promoting cytokine produced by both malignant and host cells in the tumor microenvironment 1 . It is also a downstream product of oncogenic mutations, e.g., ras and TP53 2 3 . Typically via its major downstream signal transducer STAT3, IL-6 has both local and systemic pro-tumor actions in experimental and human cancers. In the tumor microenvironment, these include stimulation of malignant cell growth and survival 4 , promotion of invasion and metastasis 5 , modulation of tumorpromoting T cell subtypes, involvement in autocrine tumor cell cytokine networks 6 , and regulation of the myeloid cell infiltrate 7 . Systemic effects of excess IL-6 production include induction of acute phase reactants and involvement in the elevated platelet count (paraneoplastic thrombocytosis) 8 that is a complication of several common human cancers.
To add to this catalogue of tumor-promoting actions, there are reports that IL-6 stimulates angiogenesis in the tumor microenvironment 9 with evidence that STAT3 signaling induces HIF-1 mediated VEGF-A transcription 10 . IL-6 is also reported to have direct effects on endothelial cell proliferation and migration 9 11 12
and has been implicated in resistance to anti-VEGF antibody treatment in patients 13 14 . In preclinical and clinical studies we found that a therapeutic neutralizing anti-IL-6 antibody reduced systemic VEGF levels in ovarian cancer patients, and that in peritoneal ovarian cancer xenografts, blood vessels were reduced, with a concomitant inhibition of the Notch ligand This led us to study further the actions of IL-6 in normal and cancer angiogenesis. In this paper we present novel evidence that IL-6 directly Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 16, 2015; DOI: 10.1158/0008-5472. CAN-15-1227 stimulates angiogenesis, but in contrast to VEGF, IL-6 stimulated vessels have defective pericyte coverage. We show that this may be due to differential regulation of Notch ligands and Ang2 by these two mediators. Our findings have implications for the use of cancer therapies that target VEGF or IL-6.
Methods

Ethics Statement
All animal experiments were approved by the local ethics review process of the Biological Services Unit, Queen Mary University of London and conducted in accordance with the UKCCCR guidelines for the welfare and use of animals in cancer research.
Aortic ring assay
Angiogenic sprouts were induced from mouse or rat thoracic aortas according to the method of Nicosia and Ottinetti 40 . Aortas were dissected from cervically dislocated 8-12 week old male C57BL/6 mice (Charles River) or 180-200g male Wistar rats (Harlan Laboratories) and sliced into 0.5 mm sections and incubated overnight in serum free OptiMEM (Invitrogen) at 37°C. Aortic rings were embedded in type I collagen (1 mg/ml) in E4 media (Invitrogen). For mouse aortic rings, the wells were supplemented with OptiMEM with 1% FBS and 30ng/ml of VEGF (R&D systems), 50ng/ml of human IL-6 (R&D systems) or 30ng/ml of mouse IL-6 (R&D systems) and incubated at 37°C, 10% CO 2 .
Rat aortic ring wells were treated with OptiMEM with 1% FBS and 10ng/ml VEGF, 10ng/ml rat IL-6 or 10nM VEGFRi (Cediranib, VEGFR2 inhibitor) and incubated at 37°C, 10% CO 2 . Angiogenic sprouts were counted after 7 days of culture for mouse aortic ring and after 4 days of culture for rat aortic rings.
The length of sprouts was quantified using ImageJ software by drawing radial lines from the base of the aortic ring to the tip of the sprouting new vessel.
Pericytes were quantified 250 microns from the tip of the aortic ring vessel to avoid false positive quantification of activated fibroblast, which are normally found at the stalk of the vessel. Animals were housed and treated in Accordance with UK Home Office Regulations.
Staining of Aortic rings
The rat and mouse aortic rings were respectively cultured for 1 and 2 weeks before the staining. The rings were washed with PBS, fixed in 4% formaldehyde for 20 minutes. The wells were then washed once in PBS and the rings were permeabilized with 0.5% Triton X-100 in PBS for 30 minutes, before being washed twice in PBS. 100μl of BS-1 Lectin FITC (1 mg/ml; Sigma, cat. no. L9381/L5264) (1:200), anti-actin, α-SMA Cy3 (Sigma, cat. no. The plates were washed twice in PBS and the rings were removed from the 96 well plate, using a syringe needle, placed on a microscope slide and mounted with Prolong Gold DAPI containing medium (Invitrogen, cat. no. P36931). The slides were left to dry and imaged using confocal microscopy (Zeiss LSM 510 META).
Tissue culture
MLEC was kindly given by Professor Kairbaan Hodivala-Dilke, was used for most of the in vitro studies. This cell line was isolated and cultured as 16 . HUVEC (HPA laboratories) were grown and cultured in endothelial growth medium (HPA laboratories) and maintained within 3-4 passages.
Ovarian cancer cell lines
The IGROV-1 line was recently characterized as a hypermutated line but unlikely to represent HGSC. The cell line was mycoplasma tested (InvivoGen, USA) and always maintained within 4-5 passages before new cells were recovered from frozen master stocks. Cells were cultured in RPMI 1640 supplemented with 10% FCS and 1% pen-strep. Cells were counted using a Vi-cell cell counter (Beckman Coulter) on days 3 and 7. were treated with VEGF (30ng/ml), human IL-6 (30ng/ml) or mouse IL-6 (30ng/ml) in 2ml of serum free MLEC medium for 6 hours or 24 hours. Cells were then washed with PBS and harvested using RIPA Buffer (R0278, Sigma UK) with 1x proteinase inhibitors. Protein quantification was performed using the Bradford reagent (Sigma-Aldrich), according to the manufacturer's instructions. Cell extracts (25 μg) were run on a NuPAGE® Novex® 4-12% Bis-Tris Gels, 1.5 mm and transferred to a nylon membrane. The membrane was blocked overnight (4°C in PBS with 0.1% Tween and 5% milk powder) and probed using the following antibodies: Jagged1 
Staining of MLEC
Scratch wound migration assay
Confluent monolayers of MLEC cells were scratched with a p20 pipette tip, cells were then washed twice with PBS prior to the addition of serum free growth medium with VEGF 100ng/ml, hIL-6 100ng/ml and mIL-6 100ng/ml.
Wounds were monitored by time lapse microscopy using an Olympus IX81 Microscope Hamamatsu Orca ER digital camera. Images were acquired every 30 minutes and subsequently analyzed using ImageJ software. Cell proliferation assay 70,000 MLEC cells were seeded in a 24 well plate. The following day cells were treated with either 50 or 100ng/ml of VEGF, human IL-6 or mouse IL-6.
The plate was then incubated for 72 hours at 37°C and 5% CO2. After incubation, the cells were trypsinized and counted using the Vi-cell counter (Beckman Coutler). Each condition was repeated in triplicate.
In vivo IGROV-1 xenografts
A total of 1x10 
Protein extraction from mouse tumors
75mg of tumor tissue was lysed with 1ml of ice-cold lysis buffer (150mM NaCl 20mM Tris, pH 7.5 1mM EDTA1mM EGTA1% Triton X-100) with protease and Phosphatase Inhibitors. Samples were then dissociated using gentleMACS Dissociator. After dissociation, samples were centrifuged at 1500 rpm for 2 minutes. Samples are always kept on ice between procedures.
Next, using a probe sonicator set at 40% amplitude, tissues were sonicated for 5-15 seconds bursts. Sonicated samples were then rotated for 30 minutes at 4°C followed by a centrifugation for 15 minutes at 13,200 rpm at 4C. The pellet was discarded and protein concentration measured. Lysates were frozen at -80°C until loaded on gels. 
Gene Expression Analysis
Table generated from a heat map established in a previous study (Coward et al).
Statistical analysis
Statistical analyses were carried out using Prism Graph Pad software.
Statistical significance was calculated using Student's t test and chi-square test. Findings are presented as standard error of the mean (SEM). 
Results
IL-6 stimulates angiogenesis in the aortic ring assay
As we had found that anti-human IL-6 reduced tumor blood vessel density in human tumor xenografts 7 , we tested the activity of human IL-6 in the aortic ring assay. This is an ex vivo model of angiogenesis that studies the effects of mediators on normal vessel sprouting. Optimal vessel sprouting was observed in the mouse aortic ring assay 7-10 days after treatment with 30ng/ml VEGF or 50ng/ml hIL-6 ( Figure 1A) . Mouse IL-6 (30ng/ml) in mouse aortas and rat IL-6 (10ng/ml) in rat aortas also stimulated vessel sprouting and there was no significant difference in the number of sprouts between the VEGF and IL-6 treatments ( Figure 1B ). VEGF and IL-6 treatments also gave similar results in terms of length of vessel sprouts ( Figure 1C ).
Other reports have described that IL-6 has indirect angiogenic activity via stimulation of VEGF production, and thus inhibition of VEGF action would also block IL-6 activity 15 . We therefore tested the action of the VEGF receptor inhibitor cediranib in the rat aortic ring assay. Cediranib significantly inhibited the sprouting activity of VEGF but had no significant activity on the actions of IL-6 in this model ( Figure 1D ). This result suggested that in the aortic ring model IL-6 may stimulate vessel sprout formation without inducing VEGF. To demonstrate that IL-6Rα is required for IL-6 mediated angiogenesis, we added an anti-IL-6Rα antibody to the IL-6 -simulated aortic ring cultures. This abolished the effect of IL-6 (data not shown). We also found that the endothelial cells of the aortic ring vessels expressed IL-6 receptor, staining positive for the gp80 IL-6 receptor alpha subunit (IL-6Rα) ( Figure 1E ).
Furthermore western blots of lysates from the aortic ring assay showed strong Figure 1F, Supplementary Figure 1) . In contrast there was strong phosphorylation of ERK in VEGF-stimulated aortic ring lysates but IL-6 had no effect ( Figure 1F, Supplementary Figure 1) .
As the aortic ring assay has a mixture of cells that could complicate any analysis of signaling pathways, we used a simpler experimental system in our next set of experiments, the MLEC mouse endothelial cell line 16 .
IL-6 has direct effects on endothelial cells
Mouse lung endothelial cells (MLEC) stained with the endothelial cell marker endomucin express IL-6Rα (Figure 2A ), and both human and mouse IL-6 at 100 ng/ml stimulated MLEC proliferation ( Figure 2B ). The IL-6 effect was not as potent as that of VEGF but was still significant. VEGF and human and mouse IL-6 were equally potent in the 'scratch' assay which measured MLEC migration ( Figure 2C ). We then used western blotting to study the VEGF and IL-6 signaling pathways in these cells. As expected, IL-6 increased STAT3 phosphorylation and VEGF increased ERK phosphorylation, but IL-6 stimulation did not affect phospho-ERK levels and VEGF had no effect on Figure 3) . Earlier time points (two hours and six hours) were also studied with similar results (data not shown). Thus, we concluded that in both the aortic ring assay and in cultures of MLEC cells, IL-6 has direct effects on endothelial cells. 
Pericyte coverage is defective in IL-6 stimulated vessels
Over the 7-10 days mouse aortic ring assay incubation period, and the 4 days of the rat aortic ring assay, pericytes also develop around the endothelial cells of the vessel sprouts when they are stimulated by VEGF. Using α-SMA as a pericyte marker, we treated mouse aortic rings with VEGF, mouse or human IL-6 and rat aortic rings with rat IL-6, and we noticed that pericyte coverage was diminished in the IL-6 stimulated cultures. Overall there were less pericytes attached to the tips of the IL-6 stimulated vessels compared to the VEGF cultures and many detached pericytes were observed in the presence of IL-6. (Figure 3A-C) . This difference between number of pericytes associated with the sprout tips in VEGF and IL-6 cultures was significant ( Figure 3D ). Similar results were observed with another pericyte marker NG2 (Supplementary Figure 4) .
Differences in VEGF and IL-6 signaling may explain defective pericyte coverage
We hypothesized that differential regulation of Notch family members may be involved in the differences in pericyte coverage between IL-6 and VEGFtreated cultures. High levels of the Notch ligand DLL4 in endothelial cells are associated with vessel maturity and good pericyte coverage 17 18 19 . Another Notch ligand, Jagged1, is associated with increased vessel sprouting and less mature vessels 20 21 . We first investigated this hypothesis in MLEC cells.
Using western blotting we found that 24 hours of treatment with IL-6 and VEGF differentially regulated the expression of DLL4 and Jagged1. While IL-6 stimulated more Jagged1 than did VEGF, VEGF had a greater effect on DLL4 than on Jagged1 ( Figure 4A, Supplementary Figure 5A ). We also observed 
Relevance of these findings to malignant disease
Our results so far would suggest that anti-IL-6 treatment would increase pericyte coverage of tumor blood vessels. We previously reported that when peritoneal xenografts of IGROV-1 ovarian cancer cells, that constitutively produce IL-6, were treated with anti-human IL-6 antibodies, vessel density was reduced, as was Jagged1 mRNA and protein 
Correlations from human ovarian cancer biopsies
Finally, we revisited a previously published analysis of mRNAs that are associated with high IL-6 expression 7 using publically available datasets of ovarian cancer. Ang2 and Jagged1 had significant a co-efficient of correlation with high IL-6 expression (p=0.015 and p=0.001 respectively) ( Figure 6A ). 
Discussion
A role for IL-6 in pathogenic angiogenesis has been suggested in diseases such as stroke, rheumatoid arthritis and various cancers 29 1 30 . In a previous publication we showed that treatment of ovarian cancer xenografts with an anti-IL-6 antibody reduced the tumor vasculature with concomitant inhibition of the NOTCH ligand Jagged1, which has been implicated in vessel sprouting 7 .
Collectively, the published literature suggested that IL-6 could drive abnormal angiogenesis and that the anti-IL-6 antibody had a potential as antiangiogenic agent. Thus we investigated the direct effects of IL-6 on normal angiogenesis using endothelial in vitro and ex vivo studies, and used the findings from those studies to explore its importance in tumor angiogenesis using peritoneal models of ovarian cancer and ovarian cancer biopsies.
We found that IL-6 is as potent as VEGF in inducing vessel sprouting in the aortic ring assay and was also able to stimulate endothelial cell migration and This is, to our knowledge, the first study showing that IL-6 can induce a type of vessel sprouting with abnormal pericyte coverage compared to VEGF.
These observations have clinical implications for malignant and other diseases, especially as studies in various cancers suggest that pericyte depletion leads to increased metastasis 22 31 32 . The ability of anti-IL-6 treatment to improve pericyte coverage of vessels in xenograft models suggests that in the tumor microenvironment, defective pericyte coverage may be due to the action of IL-6 in those tumors with high levels of this cytokine.
The regulation of Ang2 by IL-6 is another interesting finding as Ang2 expression has been shown to correlate with lymph node metastasis in various cancers 33, 34, 35 . Moreover, the angiopoietin inhibitor Trebananib increased progression-free survival in patients with recurrent ovarian cancer 36 .
As STAT3 signaling is implicated in the treatment failure of various antiangiogenic agents 13 37 38 39
, combinations of IL-6 and angiogenesis antagonists may be worthy of further study. The quantification carried out by two independent reviewers was analyzed using chi-sqaure test (n=6 per group from two independent experiments). D.
Immunohistochemistry staining for Jagged1, DLL4 and Ang2 in the IGROV-1 xenograft following 4 weeks of treatment with anti-IL-6 antibody. The images were taken from 5 randomly selected areas per tumor section (n=6 per group from two independent experiments) using a X40 microscope. E. Western blot analysis of DLL4 and Ang2 from protein extracted from in vivo IGROV-1 xenografts treated with anti-IL-6 antibody. 
